| Target Price | $147.90 |
| Price | $186.23 |
| Deviation |
20.58%
register free of charge
|
| Number of Estimates | 20 |
|
20 Analysts have issued a price target Insmed Incorporated 2026 .
The average Insmed Incorporated target price is $147.90.
This is
20.58%
register free of charge
$252.00
35.32%
register free of charge
$111.10
40.34%
register free of charge
|
|
| A rating was issued by 26 analysts: 24 Analysts recommend Insmed Incorporated to buy, 2 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Insmed Incorporated stock has an average upside potential 2026 of
20.58%
register free of charge
|
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 363.71 | 481.71 |
| 19.17% | 32.44% | |
| EBITDA Margin | -214.87% | -217.85% |
| 2.97% | 1.38% | |
| Net Margin | -251.24% | -249.79% |
| 2.30% | 0.58% |
21 Analysts have issued a sales forecast Insmed Incorporated 2025 . The average Insmed Incorporated sales estimate is
This results in the following potential growth metrics:
8 Analysts have issued an Insmed Incorporated EBITDA forecast 2025. The average Insmed Incorporated EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
22 Insmed Incorporated Analysts have issued a net profit forecast 2025. The average Insmed Incorporated net profit estimate is
This results in the following potential growth metrics and future Net Margins:
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -5.57 | -5.70 |
| 4.31% | 2.33% | |
| P/E | negative | |
| EV/Sales | 79.77 |
22 Analysts have issued a Insmed Incorporated forecast for earnings per share. The average Insmed Incorporated EPS is
This results in the following potential growth metrics and future valuations:
Insmed Incorporated...
| Analyst | Rating | Action | Date |
|---|---|---|---|
| UBS |
Locked
➜
Locked
|
Locked | Oct 31 2025 |
| RBC Capital |
Locked
➜
Locked
|
Locked | Oct 31 2025 |
| Goldman Sachs |
Locked
➜
Locked
|
Locked | Oct 31 2025 |
| Wells Fargo |
Locked
➜
Locked
|
Locked | Oct 31 2025 |
| B of A Securities |
Locked
➜
Locked
|
Locked | Oct 27 2025 |
| UBS |
Locked
➜
Locked
|
Locked | Oct 14 2025 |
| Goldman Sachs |
Locked
➜
Locked
|
Locked | Oct 03 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
UBS:
Locked
➜
Locked
|
Oct 31 2025 |
|
Locked
RBC Capital:
Locked
➜
Locked
|
Oct 31 2025 |
|
Locked
Goldman Sachs:
Locked
➜
Locked
|
Oct 31 2025 |
|
Locked
Wells Fargo:
Locked
➜
Locked
|
Oct 31 2025 |
|
Locked
B of A Securities:
Locked
➜
Locked
|
Oct 27 2025 |
|
Locked
UBS:
Locked
➜
Locked
|
Oct 14 2025 |
|
Locked
Goldman Sachs:
Locked
➜
Locked
|
Oct 03 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


